Biotron Ltd. (BIT.AX)

ASX - ASX Delayed Price. Currency in AUD
0.05+0.00 (+1.96%)
At close: 9:12 PM EDT
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close0.05
Bid0.05 x
Ask0.05 x
Day's Range0.05 - 0.05
52wk Range0.04 - 0.10
1y Target EstN/A
Market Cap16.32M
P/E Ratio (ttm)-5.20
Avg Vol (3m)193,224
Dividend & YieldN/A (N/A)
Earnings DateN/A
  • PR Newswire6 months ago

    Biotron Phase 2 Hepatitis C Trial Success

    NEW YORK, March 17, 2016 /PRNewswire/ -- Biotron Limited (BIT.AX) confirms positive outcomes from its Phase 2 study of its first-in-class antiviral drug BIT225. The trial was designed to assess the safety and antiviral activity of three month's dosing of BIT225 in patients infected with Hepatitis C virus (HCV). HCV G1 patients treated with BIT225 and IFN/RBV are significantly more likely to clear virus within 24 weeks of commencing treatment than those treated with IFN/RBV alone.

  • We're sorry this is all we were able to find about this topic.